Research Article
Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
| | Authors | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias | Quality of the literature |
| | Gligorov et al. [14] | Low risk | Low risk | High risk | Low risk | Low risk | Unclear risk | Low risk | Medium | | Bear et al. [15] | Low risk | Low risk | Unclear risk | Low risk | High risk | Low risk | Low risk | Medium | | Zielinski et al. [16] | Low risk | Low risk | High risk | Low risk | Low risk | Unclear risk | Low risk | High | | Lang et al. [17] | Low risk | Low risk | High risk | Low risk | Low risk | Low risk | Low risk | High | | Brufsky et al. [18] | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | High | | Decker et al. [19] | Low risk | Low risk | High risk | Low risk | Low risk | High risk | Low risk | Medium | | Lam et al. [8] | Low risk | Low risk | High risk | Low risk | Low risk | Low risk | Low risk | Medium | | Luck et al. [20] | Low risk | Low risk | Low risk | Low risk | High risk | Low risk | Low risk | High |
|
|
